Login / Signup

Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.

Xiaoyan LuZheng-Yi ZhouYiqiao XinMin-Jung WangEmma GrayVipul JairathJames Oliver Lindsay
Published in: Inflammatory bowel diseases (2023)
Matching-adjusted indirect comparison results suggest superiority of filgotinib 200 mg over vedolizumab IV in terms of clinical response and corticosteroid-free clinical remission in certain patient populations, noting small sample sizes and wide CIs, which may aid the selection of advanced therapies for moderately to severely active UC. A potential increased risk of serious adverse events was reported for filgotinib 200 mg vs vedolizumab IV and tofacitinib 5 mg, but findings should be interpreted with caution owing to underlying imbalances observed between the placebo groups of SELECTION and comparator trials.
Keyphrases
  • ulcerative colitis
  • case report
  • randomized controlled trial
  • patients with inflammatory bowel disease
  • disease activity